-
Australia doubles Pfizer COVID-19 vaccine order as AstraZeneca fears upend rollout

Australia has doubled its order of the Pfizer Inc COVID-19 vaccine, Prime Minister Scott Morrison said on Friday, as the country raced to overhaul its inoculation plan over concerns about the risks of blood clots with the AstraZeneca Plc vaccine.
Until late Thursday, Australia based its vaccination program largely on an AstraZeneca shot, with an order for 50 million doses - enough for the required two shots for its entire 25 million population - to be made domestically by biopharma CSL Ltd.
But Australia has now joined a host of countries in restricting use of the vaccine due to clotting concerns. Local health authorities have changed their recommendation to say the country’s nearly 12 million people aged under 50 should take the Pfizer product instead.
As a result Australia has doubled an earlier Pfizer order to 40 million shots, enough for four-fifths of the population, which would be delivered by the end of the year, Morrison said.
The policy change to Pfizer effectively ends plans to have the entire population vaccinated by the end of October.
“It is not a prohibition on the AstraZeneca vaccine,” Morrison told reporters in Canberra after a national cabinet meeting to discuss the virus response.
“For those who are over 50, there is a strong encouragement to be taking this AstraZeneca vaccine.”

After Australia opened a quarantine-free travel zone with neighboring New Zealand, Morrison said he hoped to make similar arrangements elsewhere in the region, and “the more Australians who are vaccinated, the more likelihood there is of being able to have the types of arrangements that I mentioned”.
Health Secretary Brendan Murphy called the policy change “highly precautionary” given the low rates of possible adverse effects associated with the AstraZeneca shot.
More than a dozen countries have at one time suspended use of the AstraZeneca vaccine, but most have resumed, with some, including France, the Netherlands and Germany, recommending a minimum age.
Australia’s most populous state New South Wales, home to nearly a third of the population, said it was pausing the AstraZeneca rollout to update “informed consent” documents to notify patients of risks.
Before the updated Pfizer order was announced, AstraZeneca said it respected the Australian decision and was working with regulators around the world “to understand the individual cases, epidemiology and possible mechanisms that could explain these extremely rare events”.
CSL said it remained committed to meeting its contracted arrangements to make the vaccine.
‘Eggs in one basket’
As well as the AstraZeneca and Pfizer contracts, Australia ordered 51 million doses of a vaccine being trialed by US pharmaceutical giant Novavax Inc, but local authorities say they do not expect to approve the product until late 2021.

Australia also embarked on a home-grown option - as opposed to local manufacture of AstraZeneca’s offshore-developed product - with University of Queensland undertaking a trial of its own vaccine. That trial was aborted in December when the product was linked to false positives in HIV tests.
The government said in January that it planned to have four million vaccinated by the end of March, only to have 600,000 by that time. The number was just over one million as of Friday, the authorities said.
“Australians won’t forget who is responsible for failing to deliver on what are his own promises and his own commitments,” opposition Labor leader Anthony Albanese told reporters on Friday.
“They should have listened to the expert advice that was given to the government, and indeed to all governments, about not placing all our eggs in one basket”.
New Zealand Prime Minister Jacinda Ardern said the country was still assessing the AstraZeneca vaccine, without specifying whether the Australian decision would affect it.
The Pfizer vaccine is the only inoculation approved by New Zealand, which says it has ordered enough for its five million population.
Australia began vaccinations later than some other countries because of its low number of infections, which stand at just under 29,400, with 909 deaths, since the pandemic began.
source: Reuters
Image source: Reuters
Levant
You May Also Like
Popular Posts
Caricature
BENEFIT Sponsors Gulf Uni...
- April 17, 2025
BENEFIT, the Kingdom’s innovator and leading company in Fintech and electronic financial transactions service, has announced its sponsorship of the “Innovation and Sustainable Technology Solutions Competition (GU - IST Solutions), hosted by Gulf University at its main campus.
This strategic sponsorship reflects BENEFIT’s active role in advancing technological innovation and fostering sustainable solutions to future challenges. It also seeks to empower Bahraini youth by enhancing their skills, capabilities, and competitiveness in innovation and solution development—contributing meaningfully to the broader goals of sustainable development across all sectors.
As part of BENEFIT’s active involvement in the competition, the company has announced that Hanan Abdulla Hasan, Senior Manager of Public Relations and Communication, will serve on the competition’s supervisory committee. Her upcoming participation reflects BENEFIT’s forward-looking commitment to championing academic and professional excellence.
Commenting on the occasion, Hanan Abdulla Hasan, Senior Manager of Public Relations and Communication at BENEFIT, said, “We are privileged to support this pioneering initiative, which aligns seamlessly with BENEFIT’s enduring commitment to fostering innovation and nurturing the potential of Bahrain’s youth. Our participation is rooted in a deep sense of social responsibility and a firm belief in the pivotal role of innovation in shaping a sustainable future. Through such platforms, we seek to empower the next generation with the knowledge, skills, and foresight required to develop impactful solutions that address future challenges, in line with the United Nations Sustainable Development Goals 2030.”
Dr. Aseel Al Ayash Dean of the College of Engineering in Gulf University commented, “We extend our sincere gratitude to BENEFIT for their generous sponsorship and support of the Innovation and Sustainable Technology Solutions Competition. This contribution plays an instrumental role in helping us achieve the strategic goals of this initiative, namely, cultivating a culture of innovation and sustainability, encouraging efforts that address the imperatives of sustainable development, and enhancing the practical and professional capabilities of our students and participants.”
The event will bring together a diverse spectrum of participants, including secondary school students, university undergraduates, engineers, industry professionals, entrepreneurs, academic researchers, and subject matter experts representing a wide range of disciplines.
The competition seeks to inspire participants to develop and present innovative, sustainable technologies aimed at addressing pressing environmental, social, and economic challenges. It encourages the formulation of business models that integrate advanced technological solutions with core principles of sustainability. Moreover, it serves as a platform for emerging leaders, entrepreneurs, and innovators to contribute to the advancement of the Sustainable Development Goals, promote the ethos of responsible technology, and demonstrate its transformative potential across various sectors.
Attendees will have the opportunity to view a series of project presentations submitted by participants, covering diverse areas such as eco-friendly product design, smart and sustainable innovations, renewable energy technologies, water conservation and management, waste minimisation and recycling, green architectural solutions, and sustainable transportation systems. Outstanding projects will be formally recognised and awarded at the conclusion of the event.
opinion
Report
ads
Newsletter
Subscribe to our mailing list to get the new updates!